NOVO NORDISK PHARMACEUTICALS A/S
CVR number: 24257924
Novo Alle 1, 2880 Bagsværd
tel: 44448888
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 3 941.00 | ||||
| Other operating income | 24 653.00 | 6 259.00 | |||
| Gross profit | 3 941.00 | 24 614.00 | 6 218.00 | -46.00 | |
| Costs of management | 39.00 | -38.00 | -39.00 | -41.00 | -46.00 |
| Reduction in value of non-current assets | 2 799.00 | -2 664.00 | -5 812.00 | ||
| EBIT | -39.00 | 3 903.00 | 52 027.00 | 9 772.00 | -5 904.00 |
| Other financial income | 3 761.00 | 240.00 | 16.00 | 4 674.00 | |
| Other financial expenses | -1.00 | -3 946.00 | -26 379.00 | -9 727.00 | -5.00 |
| Exchange rate differences | -2 480.00 | ||||
| Pre-tax profit | 3 721.00 | -2 283.00 | 1 034.00 | -6 157.00 | -1 189.00 |
| Income taxes | 1.00 | -85.00 | 296.00 | 714.00 | -1 069.00 |
| Net earnings | 3 722.00 | -2 368.00 | 1 330.00 | -5 443.00 | -2 258.00 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible rights | 11 831.00 | 6 000.00 | |||
| Intangible assets total | 11 831.00 | 6 000.00 | |||
| Tangible assets total | |||||
| Investments total | |||||
| Non-current loans receivable | 14 545.00 | 2 864 705.00 | 2 842 764.00 | ||
| Long term receivables total | 14 545.00 | 2 864 705.00 | 2 842 764.00 | ||
| Inventories total | |||||
| Current amounts owed by group member comp. | 120 075.00 | 193 156.00 | 37.00 | ||
| Current owed by particip. interest comp. | 3 941.00 | ||||
| Current other receivables | 6.00 | ||||
| Current deferred tax assets | 9.00 | 88 871.00 | 84 437.00 | ||
| Short term receivables total | 9.00 | 92 812.00 | 204 512.00 | 193 162.00 | 37.00 |
| Cash and bank deposits | 1 048.00 | 1 107.00 | 1 481.00 | 5 252.00 | 105 132.00 |
| Cash and cash equivalents | 1 048.00 | 1 107.00 | 1 481.00 | 5 252.00 | 105 132.00 |
| Balance sheet total (assets) | 15 602.00 | 2 958 624.00 | 3 048 757.00 | 210 245.00 | 111 169.00 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 1 001.00 | 1 002.00 | 1 002.00 | 1 002.00 | 1 002.00 |
| Shares repurchased | 2 740 000.00 | 100 000.00 | |||
| Retained earnings | 10 846.00 | 2 851 070.00 | 108 702.00 | 110 032.00 | 4 589.00 |
| Profit of the financial year | 3 722.00 | -2 368.00 | 1 330.00 | -5 443.00 | -2 258.00 |
| Shareholders equity total | 15 569.00 | 2 849 704.00 | 2 851 034.00 | 105 591.00 | 103 333.00 |
| Provisions | 88 914.00 | ||||
| Non-current other liabilities | 88 914.00 | ||||
| Non-current deferred tax liabilities | 174 818.00 | ||||
| Non-current liabilities total | 88 914.00 | 174 818.00 | |||
| Current owed to participating | 19 974.00 | ||||
| Current owed to group member | 21 071.00 | 42 552.00 | 6 773.00 | ||
| Short-term deferred tax liabilities | 62 056.00 | 1 017.00 | |||
| Other non-interest bearing current liabilities | 33.00 | 32.00 | 1 834.00 | 46.00 | 46.00 |
| Current liabilities total | 33.00 | 20 006.00 | 22 905.00 | 104 654.00 | 7 836.00 |
| Balance sheet total (liabilities) | 15 602.00 | 3 047 538.00 | 3 048 757.00 | 210 245.00 | 111 169.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.